Peculiarities of antihypertensive therapy in metabolic syndrome and diabetes mellitus
- Authors: Mychka VB1, Zhernakova Y.V1, Chazova IE1, Michka VB1, Jernakova Y.V1, Chazova IE1
-
Affiliations:
- Issue: No 11 (2009)
- Pages: 22-26
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277295
- ID: 277295
Cite item
Full Text
Abstract
Peculiarities of antihypertensive therapy in metabolic syndrome and diabetes mellitus
The prevalence of hypertension (HP) and associated with it cardiovascular risk, disability and premature death of the patients increasing. It is known that HP is frequently associated with such conditions as metabolic syndrome (MS) and type II diabetes. In patients with MS and diabetes prevalence of HP then in general population. In 80% of cases development of HP precedes to development of diabetes. Treatment of HP have in these patients have some specifics. First of all, it is necessary to achieve blood pressure goals, metabolic control and prevention of complications.
The prevalence of hypertension (HP) and associated with it cardiovascular risk, disability and premature death of the patients increasing. It is known that HP is frequently associated with such conditions as metabolic syndrome (MS) and type II diabetes. In patients with MS and diabetes prevalence of HP then in general population. In 80% of cases development of HP precedes to development of diabetes. Treatment of HP have in these patients have some specifics. First of all, it is necessary to achieve blood pressure goals, metabolic control and prevention of complications.
Keywords
References
- Zimmet P, Shaw J, Alberti G. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic medicine 2003;20(9):693-702.
- Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2008. 319 с.
- Руководство по артериальной гипертонии / Под ред. Е.И. Чазова, И.Е. Чазовой. М., 2005. 784 с.
- Мычка В.Б., Чазова И.Е. Российская доказательная медицина - программа МИНОТАВР: преимущества ретардной формы индапамида при лечении метаболического синдрома // Consilium medicum. 2006. Т. 8. № 5. С. 46-50.
- Dahlof B, Sever PS, Poulter NR, et al, for the ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs atenolol adding bendroflumethiazide as required, in the ASCOT-BPLA: a multicenter randomised controlled trial. Lancet 2005;366:895-906.
- The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
- Чазова И.Е., Мычка В.Б., Горностаев В.В. и др. Цереброваскулярные осложнения у больных артериальной гипертонией: первичная и вторичная профилактика // Consilium medicum. 2003. Т. 5. № 2. С. 61-64.
- Brown M, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
- Pepine CJ, Kowey PR, Kupfer S, et al. INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006;47:547-51.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
- Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:13:905-12.
- Чазова И.Е., Ратова Л.Г. КЛИП-АККОРД: полнодозовая фиксированная комбинация в лечении 6346 пациентов с артериальной гипертензией // Consilium medicum. Болезни сердца и сосудов. 2006. Т. 1. № 3.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2334&mid=1085056570&magid=175&full=1
Supplementary files
